Novel Science.
Expert Leadership.

Jasper Therapeutics’ management team is comprised of experienced biopharma industry veterans with extensive track records in drug development and commercialization. With this leadership, we are well positioned to achieve our vision of exponentially expanding the eligible patient population both for allogeneic and autologous gene edited hematopoietic stem cell therapy.


Ronald Martell

Chief Executive Officer

Jeet Mahal

Chief Operating Officer

Edwin Tucker, M.D.

Chief Medical Officer

Herb Cross

Chief Financial Officer

Wendy Pang, M.D., Ph.D.

Senior Vice President, Research and Translational Medicine

David Hinds

Senior Vice President, Development Operations

Patricia Carlos

Senior Vice President, Regulatory Affairs & Quality

Luca Di Noto, Ph.D.

Senior Vice President, Technical Operations

Arjun Agarwal, CPA

Vice President, Finance and Corporate Controller

David Ku, M.D.

Vice President, Corporate Development, Portfolio Strategy & Management

Annette Marcantonio

Vice President, Clinical Operations

Matt Ford

Vice President, Human Resources

Board Of Directors

Bill Lis

Judith Shizuru, M.D., Ph.D.

Kurt von Emster

Anna French, Ph.D.

Chris Nolet

Vishal Kapoor

Scott Brun, M.D.

Ronald Martell

Scientific Advisory Board

Jasper Therapeutics has established a premier, world-class Scientific Advisory Board of accomplished scientific leaders who are experts in immunology, blood and bone marrow transplantation, stem cell and gene therapy, and hematologic cancers.

Judith Shizuru, M.D., Ph.D.

Art Weiss, M.D., Ph.D.

Fred Appelbaum, M.D.

Jeffrey Ravetch, M.D., Ph.D.

Harry Malech, M.D.

Stephen J. Galli, M.D.

Dan Adelman, M.D.